Cardioprotective role of β-blockers and angiotensin antagonists in early-onset anthracyclines-induced cardiotoxicity in adult patients: A systematic review and meta-analysis

Postgraduate Medical Journal

Volumn 91, Issue 1081, 2015, Pages 627-633

  Yun, Seongseok ^a   Vincelette, Nicole D ^b   Abraham, Ivo ^c,d  

^a UNIVERSITY OF ARIZONA COLLEGE OF MEDICINE   (United States)

^b MAYO GRADUATE SCHOOL   (United States)

^c Center for Health Outcomes and PharmacoEconomic Research   (United States)

^d UNIVERSITY OF ARIZONA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANGIOTENSIN ANTAGONIST; ANTHRACYCLINE; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CARVEDILOL; ENALAPRIL; METOPROLOL; NEBIVOLOL; TELMISARTAN; ANGIOTENSIN DERIVATIVE; ANTINEOPLASTIC ANTIBIOTIC; CARDIOTONIC AGENT;

ARTICLE; ATTRIBUTABLE RISK; CARDIOMYOPATHY; CARDIOTOXICITY; CARDIOTOXOCITY; DRUG INDUCED DISEASE; HEART LEFT VENTRICLE FUNCTION; HEART PROTECTION; HODGKIN DISEASE; HUMAN; META ANALYSIS; NONHODGKIN LYMPHOMA; RANDOMIZED CONTROLLED TRIAL (TOPIC); SYSTEMATIC REVIEW; SYSTEMATIC REVIEW (TOPIC); ANTAGONISTS AND INHIBITORS; CHEMICALLY INDUCED; DRUG EFFECTS; HEART STROKE VOLUME; NEOPLASMS; PATHOPHYSIOLOGY; PREVENTION AND CONTROL;

ADRENERGIC BETA-ANTAGONISTS; ANGIOTENSINS; ANTHRACYCLINES; ANTIBIOTICS, ANTINEOPLASTIC; CARDIOTONIC AGENTS; CARDIOTOXICITY; HUMANS; NEOPLASMS; RANDOMIZED CONTROLLED TRIALS AS TOPIC; STROKE VOLUME; VENTRICULAR DYSFUNCTION, LEFT;

EID: 84945467238     PISSN: 00325473     EISSN: 14690756     Source Type: Journal    
DOI: 10.1136/postgradmedj-2015-133535     Document Type: Article

References (40)

1. Minotti G, Menna P, Salvatorelli E, et al. Anthracyclines: molecular advances and pharmacologic developments in antitumor activity and cardiotoxicity. Pharmacol Rev 2004;56:185–229.
2. Swain SM, Whaley FS, Ewer MS. Congestive heart failure in patients treated with doxorubicin: a retrospective analysis of three trials. Cancer 2003;97: 2869–79.
3. Steinherz LJ, Steinherz PG, Tan CT, et al. Cardiac toxicity 4 to 20 years after completing anthracycline therapy. JAMA 1991;266:1672–7.
4. Pinder MC, Duan Z, Goodwin JS, et al. Congestive heart failure in older women treated with adjuvant anthracycline chemotherapy for breast cancer. J Clin Oncol 2007;25:3808–15.
5. Zhang S, Liu X, Bawa-Khalfe T, et al. Identification of the molecular basis of doxorubicin-induced cardiotoxicity. Nat Med 2012;18:1639–42.
6. Fajardo G, Zhao M, Berry G, et al. β2-adrenergic receptors mediate cardioprotection through crosstalk with mitochondrial cell death pathways. J Mol Cell Cardiol 2011;51:781–9.
7. Barron TI, Connolly RM, Sharp L, et al. Beta blockers and breast cancer mortality: a population- based study. J Clin Oncol 2011;29:2635–44.
8. Soga M, Kamal FA, Watanabe K, et al. Effects of angiotensin II receptor blocker (candesartan) in daunorubicin-induced cardiomyopathic rats. Int J Cardiol 2006;110:378–85.
9. Toko H, Oka T, Zou Y, et al. Angiotensin II type 1a receptor mediates doxorubicin-induced cardiomyopathy. Hypertens Res 2002;25:597–603.
10. Kalam K, Marwick TH. Role of cardioprotective therapy for prevention of cardiotoxicity with chemotherapy: a systematic review and meta-analysis. Eur J Cancer 2013;49:2900–9.
11. Chen J, Long JB, Hurria A, et al. Incidence of heart failure or cardiomyopathy after adjuvant trastuzumab therapy for breast cancer. J Am Coll Cardiol 2012;60:2504–12.
12. Moher D, Liberati A, Tetzlaff J, et al. Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. J Clin Epidemiol 2009;62:1006–12.
13. Higgins JP, Green S. Cochrane Handbook for systematic reviews of interventions version 5.1.0. [updated March 2011]. The Cochrane Collaboration, 2011. http://www.cochrane-handbook.org
14. Higgins JP, Thompson SG, Deeks JJ, et al. Measuring inconsistency in meta-analyses. BMJ 2003;327:557–60.
15. Lipshultz SE, Lipsitz SR, Sallan SE, et al. Long-term enalapril therapy for left ventricular dysfunction in doxorubicin-treated survivors of childhood cancer. J Clin Oncol 2002;20:4517–22.
16. Seicean S, Seicean A, Alan N, et al. Cardioprotective effect of beta-adrenoceptor blockade in patients with breast cancer undergoing chemotherapy: follow-up study of heart failure. Circ Heart Fail 2013;6:420–6.
17. Smith LA, Cornelius VR, Plummer CJ, et al. Cardiotoxicity of anthracycline agents for the treatment of cancer: systematic review and meta-analysis of randomised controlled trials. BMC Cancer 2010;10:337.
18. Nakamae H, Tsumura K, Terada Y, et al. Notable effects of angiotensin II receptor blocker, valsartan, on acute cardiotoxic changes after standard chemotherapy with cyclophosphamide, doxorubicin, vincristine, and prednisolone. Cancer 2005;104:2492–8.
19. Silber JH, Cnaan A, Clark BJ, et al. Enalapril to prevent cardiac function decline in long-term survivors of pediatric cancer exposed to anthracyclines. J Clin Oncol 2004;22:820–8.
20. El-Shitany NA, Tolba OA, El-Shanshory MR, et al. Protective effect of carvedilol on adriamycin-induced left ventricular dysfunction in children with acute lymphoblastic leukemia. J Card Fail 2012;18:607–13.
21. Liu L, Liu ZZ, Liu YY, et al. [Preventive effect of low-dose carvedilol combined with candesartan on the cardiotoxicity of anthracycline drugs in the adjuvant chemotherapy of breast cancer]. Zhonghua Zhong Liu Za Zhi 2013;35:936–40.
22. Bosch X, Esteve J, Sitges M, et al. Prevention of chemotherapy-induced left ventricular dysfunction with enalapril and carvedilol: rationale and design of the OVERCOME trial. J Card Fail 2011;17:643–8.
23. Bosch X, Sitges M, Rovira M, et al. Reply: Enalapril and carvedilol for preventing chemotherapy-induced left ventricular systolic dysfunction in patients with malignant hemopathies. J Am Coll Cardiol 2013;62:2452.
24. Florenzano F, Salman P. Carvedilol for anthracycline cardiomyopathy prevention. J Am Coll Cardiol 2007;49:2142; author reply 2142–2143.
25. Cadeddu C, Piras A, Mantovani G, et al. Protective effects of the angiotensin II receptor blocker telmisartan on epirubicin-induced inflammation, oxidative stress, and early ventricular impairment. Am Heart J 2010;160:487.1–7.
26. Dessì M, Piras A, Madeddu C, et al. Long-term protective effects of the angiotensin receptor blocker telmisartan on epirubicin-induced inflammation, oxidative stress and myocardial dysfunction. Exp Ther Med 2011;2:1003–9.
27. Kalay N, Basar E, Ozdogru I, et al. Protective effects of carvedilol against anthracycline-induced cardiomyopathy. J Am Coll Cardiol 2006;48:2258–62.
28. Cardinale D, Colombo A, Sandri MT, et al. Prevention of high-dose chemotherapy-induced cardiotoxicity in high-risk patients by angiotensin-converting enzyme inhibition. Circulation 2006;114:2474–81.
29. Georgakopoulos P, Roussou P, Matsakas E, et al. Cardioprotective effect of metoprolol and enalapril in doxorubicin-treated lymphoma patients: a prospective, parallel-group, randomized, controlled study with 36-month follow-up. Am J Hematol 2010;85:894–6.
30. Bosch X, Rovira M, Sitges M, et al. Enalapril and carvedilol for preventing chemotherapy-induced left ventricular systolic dysfunction in patients with malignant hemopathies: the OVERCOME trial (preventiOn of left Ventricular dysfunction with Enalapril and caRvedilol in patients submitted to intensive ChemOtherapy for the treatment of Malignant hEmopathies). J Am Coll Cardiol 2013;61:2355–62.
31. Kaya MG, Ozkan M, Gunebakmaz O, et al. Protective effects of nebivolol against anthracycline-induced cardiomyopathy: a randomized control study. Int J Cardiol 2013;167:2306–10.
32. Dessì M, Madeddu C, Piras A, et al. Long-term, up to 18 months, protective effects of the angiotensin II receptor blocker telmisartan on Epirubin-induced inflammation and oxidative stress assessed by serial strain rate. Springerplus 2013;2:198.
33. Keefe DL. Anthracycline-induced cardiomyopathy. Semin Oncol 2001;28(4 Suppl 12):2–7.
34. Yeh ET, Tong AT, Lenihan DJ, et al. Cardiovascular complications of cancer therapy: diagnosis, pathogenesis, and management. Circulation 2004;109:3122–31.
35. Chapman JA, Meng D, Shepherd L, et al. Competing causes of death from a randomized trial of extended adjuvant endocrine therapy for breast cancer. JNatl Cancer Inst 2008;100:252–60.
36. NCCN Clinical Practice Guideline. 2014. http://www.nccn.org/professionals/ physician_gls/f_guidelines.asp
37. Ewer MS, Ali MK, Mackay B, et al. A comparison of cardiac biopsy grades and ejection fraction estimations in patients receiving Adriamycin. J Clin Oncol 1984;2:112–17.
38. Wang TJ, Evans JC, Benjamin EJ, et al. Natural history of asymptomatic left ventricular systolic dysfunction in the community. Circulation 2003;108:977–82.
39. Cardinale D, Sandri MT, Colombo A, et al. Prognostic value of troponin I in cardiac risk stratification of cancer patients undergoing high-dose chemotherapy. Circulation 2004;109:2749–54.
40. Lipshultz SE, Miller TL, Scully RE, et al. Changes in cardiac biomarkers during doxorubicin treatment of pediatric patients with high-risk acute lymphoblastic leukemia: associations with long-term echocardiographic outcomes. J Clin Oncol 2012;30:1042–9.